Imfinzi shows OS benefit in non-progressing NSCLC trial

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Imfinzi durvalumab improved overall survival vs. placebo, meeting the second of two primary endpoints in a Phase III trial to treat stage III unresectable non-small cell lung cancer that has not progressed following chemoradiation.

Imfinzi had already met the PACIFIC trial's other primary endpoint, which evaluated progression-free survival (PFS). The human IgG1 mAb targeting PD-L1 led to PFS of 16.8 months vs. 5.6 months for placebo (HR=0.52, 95% CI: 0.42, 0.65, p<0.001) in the trial's "all-comer" population (see BioCentury Extra, Sept. 11, 2017)...